500 related articles for article (PubMed ID: 17897883)
21. Zinc finger antiviral protein inhibits coxsackievirus B3 virus replication and protects against viral myocarditis.
Li M; Yan K; Wei L; Yang J; Lu C; Xiong F; Zheng C; Xu W
Antiviral Res; 2015 Nov; 123():50-61. PubMed ID: 26343012
[TBL] [Abstract][Full Text] [Related]
22. Expression of cytokine mRNAs in murine hearts with acute myocarditis caused by coxsackievirus b3.
Seko Y; Takahashi N; Yagita H; Okumura K; Yazaki Y
J Pathol; 1997 Sep; 183(1):105-8. PubMed ID: 9370955
[TBL] [Abstract][Full Text] [Related]
23. TRIF is a critical survival factor in viral cardiomyopathy.
Riad A; Westermann D; Zietsch C; Savvatis K; Becher PM; Bereswill S; Heimesaat MM; Lettau O; Lassner D; Dörner A; Poller W; Busch M; Felix SB; Schultheiss HP; Tschöpe C
J Immunol; 2011 Feb; 186(4):2561-70. PubMed ID: 21239721
[TBL] [Abstract][Full Text] [Related]
24. AIM2 Co-immunization with VP1 Is Associated with Increased Memory CD8 T Cells and Mounts Long Lasting Protection against Coxsackievirus B3 Challenge.
Yin L; Chai D; Yue Y; Dong C; Xiong S
Front Cell Infect Microbiol; 2017; 7():247. PubMed ID: 28642849
[TBL] [Abstract][Full Text] [Related]
25. The heart-protective mechanism of Qishaowuwei formula on murine viral myocarditis induced by CVB3.
Fengqin L; Yulin W; Xiaoxin Z; Youpeng J; Yan C; Qing-qing W; Hong C; Jia S; Lei H
J Ethnopharmacol; 2010 Feb; 127(2):221-8. PubMed ID: 19932162
[TBL] [Abstract][Full Text] [Related]
26. Coxsackievirus B3-induced myocarditis. Characterization of stable attenuated variants that protect against infection with the cardiovirulent wild-type strain.
Zhang H; Morgan-Capner P; Latif N; Pandolfino YA; Fan W; Dunn MJ; Archard LC
Am J Pathol; 1997 Jun; 150(6):2197-207. PubMed ID: 9176409
[TBL] [Abstract][Full Text] [Related]
27. Recombinant lentivirus-delivered short hairpin RNAs targeted to conserved coxsackievirus sequences protect against viral myocarditis and improve survival rate in an animal model.
Kim YJ; Ahn J; Jeung SY; Kim DS; Na HN; Cho YJ; Yun SH; Jee Y; Jeon ES; Lee H; Nam JH
Virus Genes; 2008 Feb; 36(1):141-6. PubMed ID: 18172750
[TBL] [Abstract][Full Text] [Related]
28. Coxsackievirus-induced myocarditis is dependent on distinct immunopathogenic responses in different strains of mice.
Huber SA
Lab Invest; 1997 May; 76(5):691-701. PubMed ID: 9166288
[TBL] [Abstract][Full Text] [Related]
29. Coxsackievirus B3-induced myocarditis in MHC class II-deficient mice.
Leipner C; Borchers M; Merkle I; Stelzner A
J Hum Virol; 1999; 2(2):102-14. PubMed ID: 10225212
[TBL] [Abstract][Full Text] [Related]
30. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration.
Song X; Liu Z; Wang H; Xin Y; Wang X; Chen J; Shi Y; Zhang C; Hui R
Exp Biol Med (Maywood); 2007 Dec; 232(11):1441-8. PubMed ID: 18040068
[TBL] [Abstract][Full Text] [Related]
31. NOD2 (Nucleotide-Binding Oligomerization Domain 2) Is a Major Pathogenic Mediator of Coxsackievirus B3-Induced Myocarditis.
Tschöpe C; Müller I; Xia Y; Savvatis K; Pappritz K; Pinkert S; Lassner D; Heimesaat MM; Spillmann F; Miteva K; Bereswill S; Schultheiss HP; Fechner H; Pieske B; Kühl U; Van Linthout S
Circ Heart Fail; 2017 Sep; 10(9):. PubMed ID: 28912259
[TBL] [Abstract][Full Text] [Related]
32. Molecular mimicry, anti-coxsackievirus B3 neutralizing monoclonal antibodies, and myocarditis.
Gauntt CJ; Arizpe HM; Higdon AL; Wood HJ; Bowers DF; Rozek MM; Crawley R
J Immunol; 1995 Mar; 154(6):2983-95. PubMed ID: 7533190
[TBL] [Abstract][Full Text] [Related]
33. Protective effects of losartan in mice with chronic viral myocarditis induced by coxsackievirus B3.
Zhang YY; Li JN; Xia HH; Zhang SL; Zhong J; Wu YY; Miao SK; Zhou LM
Life Sci; 2013 Jul; 92(24-26):1186-94. PubMed ID: 23702425
[TBL] [Abstract][Full Text] [Related]
34. An Albumin-Binding Domain Peptide Confers Enhanced Immunoprotection Against Viral Myocarditis by CVB3 VP1 Vaccine.
Gao Y; Yue Y; Xiong S
Front Immunol; 2021; 12():666594. PubMed ID: 34630378
[No Abstract] [Full Text] [Related]
35. Virus receptor trap neutralizes coxsackievirus in experimental murine viral myocarditis.
Lim BK; Choi JH; Nam JH; Gil CO; Shin JO; Yun SH; Kim DK; Jeon ES
Cardiovasc Res; 2006 Aug; 71(3):517-26. PubMed ID: 16806133
[TBL] [Abstract][Full Text] [Related]
36. Viral damage or 'molecular mimicry'-placing the blame in myocarditis.
Rose NR
Nat Med; 2000 Jun; 6(6):631-2. PubMed ID: 10835674
[No Abstract] [Full Text] [Related]
37. Using recombinant coxsackievirus B3 to evaluate the induction and protective efficacy of CD8+ T cells during picornavirus infection.
Slifka MK; Pagarigan R; Mena I; Feuer R; Whitton JL
J Virol; 2001 Mar; 75(5):2377-87. PubMed ID: 11160741
[TBL] [Abstract][Full Text] [Related]
38. Phyllaemblicin B inhibits Coxsackie virus B3 induced apoptosis and myocarditis.
Wang YF; Wang XY; Ren Z; Qian CW; Li YC; Kaio K; Wang QD; Zhang Y; Zheng LY; Jiang JH; Yang CR; Liu Q; Zhang YJ; Wang YF
Antiviral Res; 2009 Nov; 84(2):150-8. PubMed ID: 19699238
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity of a DNA vaccine for coxsackievirus B3 in mice: protective effects of capsid proteins against viral challenge.
Kim JY; Jeon ES; Lim BK; Kim SM; Chung SK; Kim JM; Park SI; Jo I; Nam JH
Vaccine; 2005 Feb; 23(14):1672-9. PubMed ID: 15705471
[TBL] [Abstract][Full Text] [Related]
40. Expression of vascular cell adhesion molecule-1 in murine hearts with acute myocarditis caused by coxsackievirus B3.
Seko Y; Yagita H; Okumura K; Yazaki Y
J Pathol; 1996 Dec; 180(4):450-4. PubMed ID: 9014868
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
